GSK plc (LON:GSK)
United Kingdom · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 76.21B +7.0% |
| Revenue (ttm) | 33.54B +4.3% |
| Net Income | 4.35B -20.8% |
| EPS | 1.07 -19.7% |
| Shares Out | 4.01B |
| PE Ratio | 17.82 |
| Forward PE | 10.24 |
| Dividend | 0.68 (3.58%) |
| Ex-Dividend Date | Nov 12, 2026 |
| Volume | 4,345,244 |
| Open | 1,910.00 |
| Previous Close | 1,887.00 |
| Day's Range | 1,889.00 - 1,918.50 |
| 52-Week Range | 1,690.00 - 2,282.00 |
| Beta | 0.28 |
| Analysts | Hold |
| Price Target | 2,147.38 (+12.96%) |
| Earnings Date | Oct 28, 2026 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It a... [Read more]
Financial Performance
In 2025, GSK plc's revenue was 32.67 billion, an increase of 4.11% compared to the previous year's 31.38 billion. Earnings were 5.72 billion, an increase of 121.98%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for GSK stock is "Hold." The 12-month stock price target is 2,147p, which is an increase of 12.96% from the latest price.
News
GSK price target lowered to 2,050 GBp from 2,100 GBp at Citi
Citi lowered the firm’s price target on GSK (GSK) to 2,050 GBp from 2,100 GBp and keeps a Neutral rating on the shares.
GSK price target lowered to 2,050 GBp from 2,100 GBp at Citi
Citi analyst Graham Parry lowered the firm’s price target on GSK (GSK) to 2,050 GBp from 2,100 GBp and keeps a Neutral rating on the shares.
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
GSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, ...
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus ...
GSK plc Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
R&D is centered on human causal evidence, responder biomarkers and predictive combinations. Next-year priorities include IL-33 airway milestones, data from six pivotal TSLP studies and planned phase III programs in food allergy and spontaneous urticaria.
GSK plc Announces Provisional Dividend Dates for 2027
GSK plc, whose filing was received under BlackRock ETF Trust II - iShares Flexible Income Active ETF, has announced its provisional dividend dates for 2027. The company noted that these dates are indi...
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
British drugmaker GSK has settled lawsuits that accused Moderna's [COVID-19 vaccines Spikevax and mNEXSPIKE and RSV shot mResvia of infringing its patents, the companies said on Friday.
GSK showcases progress in liver portfolio at AASLD 2026
GSK (GSK) will present new data from its advancing liver portfolio at the American Association for the Study of Liver Diseases, AASLD, The Liver Meeting 2026, taking place in Denver,…
GSK’s ViiV Healthcare commits $100M to build local HIV care networks in US
ViiV Healthcare, the global specialist HIV company majority owned by GSK (GSK), with Shionogi as a shareholder, announced a $100M, three-year commitment through its U.S. Positive Action program, to pr...
Ex-GSK boss Emma Walmsley hired to take controls of US tech giant HP
Former GSK boss Emma Walmsley has been hired to take the controls of US-based computer maker HP as it grapples with AI-driven turbulence.
Who is HP’s new CEO Emma Walmsley?
HP Inc. named former GSK chief and Microsoft board member Emma Walmsley as CEO to steer the PC maker through a memory-chip shortage.
Who is HP's new CEO Emma Walmsley?
HP Inc on Wednesday named former GSK chief and Microsoft board member Emma Walmsley as CEO to steer the PC maker through a memory-chip shortage that has driven up prices and triggered a steep industry...
HP Inc. appoints Emma Walmsley as CEO
HP Inc. (HPQ) announced that its board of directors has unanimously appointed Emma Walmsley as CEO, effective January 4, 2027. Walmsley most recently served as CEO of GSK (GSK) and…
HP names former GSK chief Emma Walmsley as CEO
HP Inc on Wednesday named former GSK chief and Microsoft board member Emma Walmsley as CEO to steer the PC maker through a memory-chip shortage that has driven up prices and triggered a steep industry...
Alamar Biosciences partners with GSK on 60,000-sample proteomic study
Alamar Biosciences (ALMR) announced a strategic scientific collaboration with GSK (GSK) that will use Alamar’s NULISA platform in a large-scale study examining how circulating protein signatures relat...
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
FREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced a ...
Broker tips: Haleon, GSK, Shell, Sainsbury, HSBC
Our broker tips, recommendations and target price updates of the week - Haleon, GSK, Shell, Sainsbury and HSBC
GSK price target lowered to 1,925 GBp from 1,975 GBp at RBC Capital
RBC Capital analyst Trung Huynh lowered the firm’s price target on GSK (GSK) to 1,925 GBp from 1,975 GBp and keeps a Sector Perform rating on the shares. Published first…
Jefferies downgrades GSK on reduced earnings momentum
Jefferies downgraded GSK (GSK) to Hold from Buy with a price target of $55.90, down from $67.40. The stock’s discount to peers has persisted due to perceptions of an earnings…
Glaxo shares slump amid concerns over its vaccine pipeline of new drugs as patent losses loom
The pharmaceutical giant reported beat third-quarter sales and profit expectations, driven by a 15% rise in demand for its specialty HIV and respiratory medicines.
GSK (GSK) Q3 2026 Earnings Call Transcript
Specialty medicines surged 15% as oncology and respiratory treatments drove growth.
What GSK (GSK) Said on Its Q3 Earnings Call
GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit in...
What GSK (GSK) Said on Its Q3 Earnings Call
MarketBeat Week in Review – 06/08 - 06/12GSK (NYSE:GSK) reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and...
GSK Tumbles As Vaccine Sales Dip, Dragging On Topline Beat
GSK stock toppled early Wednesday after the company's third-quarter vaccine sales fell short, outshining a solid topline.
GSK shares dive as weaker sales and mounting costs unnerve investors
British pharma company reports declining profits amid concerns over looming patent loss of its blockbuster HIV drug Shares in GSK slid on Wednesday despite the UK drugmaker reporting better-than-expec...